Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Financing
Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
Details : The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010 for the treatment of obesity.
Brand Name : RES-010
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Sunstone Life Science Ventures
Deal Size : $11.0 million
Deal Type : Series A Financing
Resalis Raises Series A to Complete First Clinical Trial for RES-010 in Obesity
Details : The proceeds will be used to initiate and complete the first-in-human Phase 1 clinical trial and reach Phase 2 readiness for Resalis’ lead program RES-010, a non-coding RNA-based compound, in obesity.
Brand Name : RES-010
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 04, 2024
Lead Product(s) : RES-010
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Sunstone Life Science Ventures
Deal Size : $11.0 million
Deal Type : Series A Financing
Lead Product(s) : Non-Coding RNA-Based Therapy
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Claris Ventures
Deal Size : $10.6 million
Deal Type : Financing
Details : The funding will support the finalization of IND-enabling studies for the company’s lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty liver disease (NAFLD).
Brand Name : RES-010
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 22, 2023
Lead Product(s) : Non-Coding RNA-Based Therapy
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Claris Ventures
Deal Size : $10.6 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?